HanchorBio and Aston Sci Join Forces to Unlock the Potential of Next-Generation Immunotherapy Through Cancer Vaccine Combinations
Strategic collaboration pairs HCB101 (macrophage CD47-SIRPα blockade) with Aston Sci's Phase 2 HER2-directed DNA vaccine (AST-301) to drive durable, dual innate/adaptive antitumor immunity Initial studies focus on gastric and breast cancers; expands to evaluate AST-301 and investigational...
Covered in this story
Call it yourself
No calls on $DNA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Ginkgo Bioworks Holdings Inc Class →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.